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An estimated 4 million individuals in the USA are chronically infected with the hepatitis C virus. Annually 8,000 to 10,000 of these subjects will die of liver-related complications and approximately 1,000 will require liver transplantation. The United States military have rates of HCV infection similar to the general US population (1.6%). However, it is a younger population and its natural history of HCV infection has not been studied. Therefore, the clinical outcome of HCV-infected military subjects and risk factors contributing to disease progression are largely unknown. Such knowledge is essential for decisions regarding optimal management and prevention of the disease. This study focuses on active duty military subjects infected with HCV, who will be enrolled and observed prospectively over four years (48 months). Liver biopsies are to be performed at initiation if needed and at completion of study to observe for disease progression. Lab evaluation of virologic and biochemical indicators of the disease and detailed information about risk factors, and quality of life are collected by questionnaire every six months. Currently, 90 subjects have been enrolled and 77 subjects are being followed. It is too early to analyze the data in terms of disease progression and potential contributing factors to disease progression specific to this population, as only 3 subjects have completed the study. Therefore, the data presented in this report will be confined to descriptive statistics of the sample to date. 
INTRODUCTION
An estimated 4 million individuals in the USA are chronically infected with the Hepatitis C virus. Annually, 8,000 to 10,000 of these people will die of liver related complications and approximately 20,000 are waitlisted for liver transplantation with 20% actually receiving a new liver. Thus, HCV is a major public health problem. The US military population has rates of HCV infection similar to the general US population with an overall rate of 1.6%. However, it is a younger population and the natural history of HCV infection in the population has not been studied. Therefore, the clinical outcome of HCV infected military subjects is largely unknown. Specific factors in military life have not been studied to observe if they contribute to disease progression. Such knowledge is essential for decisions regarding optimal prevention and management of the disease.
Active duty service members with chronic HCV infection will be enrolled and observed prospectively over four years in this study. Our principal hypothesis is that in active duty members infected with HCV genotype-1, liver disease progresses more rapidly than in subjects infected with HCV non-genotype-1. The effect of other factors that might influence histologic progression of liver disease including age, race, rank, deployment, alcohol consumption, and HCV RNA level will be assessed. To test this hypothesis we have the following specific aims:
"* To compare the rate of progression of liver disease based on a histologic severity scale in military subjects infected with genotype-1 to the rate of progression in those infected with non-genotype- Because of enrollment below our expected subject participation, a previous review had requested that we conduct a sample size analysis to determine the minimum number of subjects in the study to be able to conduct valid statistical analysis. The number of subjects varies between 120 and 160 depending on the difference of study characteristics in the studie'd groups (genotype 1 vs.. non-l, officer vs.. enlisted, cirrhosis vs.. non-cirrhosis, etc). However, if the difference was striking (in the order of 25% to 30%), a sample size of 43 subjects per group would be enough, we plan to finish enrollment in October 2006, we asked our NNMC colleagues to send eligible subjects to our Liver Clinic to increase our 'n' to our goal of 120 subjects. A no cost extension will be requested to improve our enrollment figures.
This is not an interventional study, no adverse events have been reported since the last APR.
At this point, 3 subjects have completed the study. Due to this number being so small, inferences cannot be made about histological progression until there is complete study data including the second liver biopsy for a greater number of subjects. However, the existing active sample including the 3 completed patients can be described as follows:
Sample Demographics: 0 82% of the sample is male. * The current ages of the subjects range from 22 to 59. The mean age is 44. * 22% of the sample is African American. 60% are Caucasian, 10% are Latino, 5 % are Asian, and 3% are of unknown ethnicity (see figure 2) . * 24% of our sample completed high school, 59% had at least some college, and 17% of the sample had postgraduate education. * 50% of the sample had a household income of>$50,000, 35% had a household income of $25,000-$50,000, 13% had a household income between $10,000 and $25,000, 1% had a household income of <$10,000, and 1% declined to answer. * 78% of the sample is enlisted. * 36% of the sample think they have had HCV for at least 10 years, 24% think they have had it less than 10 years, and 40% of the sample declined to answer or didn't know. We were able to examine this preliminary data to see if any trends or patterns emerged, specifically with respect to our aim of determining if there were any specific risk factors for acquisition of genotype-1 compared to nongenotype-1 HCV (see tables 1 and 2). Although not significant, trends emerged suggesting, in general, genotype-1 infected individuals may be more likely to have lifestyle risk factors whereas, genotype non-1 may be more likely to have other risk factors. Looking at the relationship between genotype and demographics revealed that 61.9% of officers were genotype-1 while 83.1% of the enlisted subjects were genotype-1 (see figure 4) . This difference was not significant. * 21.7% of the sample feels that they have been limited by their HCV in the past two weeks in performing their daily work at least some of the time during the past two weeks. * 20.3% of the sample feels that their HCV has limited their activities (walking, climbing, stairs, carrying groceries, playing sports) at least some of the time in the past two weeks. * 37.7% of the sample has had difficulty sleeping at night at least some of the time during the last two weeks. * 30.4% of the sample worried at least some of the time during the past two weeks that their symptoms will develop into major problems. * 26.1% of the sample worried at least some of the time during the past two weeks that they might die earlier than expected because of their Hepatitis C. * 21.7% of the sample experienced emotional stress or strain in their relationships at least some of the time during the past two weeks as a result of their hepatitis C.
These data are generated from the chronic liver disease questionnaire-HCV (CLDQ-HCV), which is asked at baseline and each patient visit. The above results express how subjects (n=90) felt at their most recent visit. An additional Quality of Life questionnaire, the SF-36 of Hepatitis Quality of Life Questionnaire (HQLQ), is also administered at each visit. Upon completion of the study, HQLQ data will be scored by a professional scoring service, therefore, no analysis is available at the time of this report.
Therapy Outcomes
Although the subjects enrolled in this study do not receive any anti viral therapy as a part of the study, a number of subjects are/have been enrolled in other studies involving treatment and/or have received such treatment at the WRAMC Liver Clinic. The below statistics were calculated for the 90 patients that were enrolled for the study. * 56% (n=50) of the sample has been exposed to an Interferon treatment while participating in this study. * Of those exposed to Interferon treatment, currently, 
CONCLUSIONS
Inferences cannot be made about histological progression of hepatitis C in this population as there have only been three subjects that have completed the study. Until there are more patients with complete study data including the second liver biopsy conclusions are unavailable. However, interesting trends are beginning to emerge with respect to genotype, military rank, and risk factors. As more data is obtained, analysis that looks at the other indicators of disease progression such as biochemical markers will also be able to be performed. Additionally, it is hoped that the morbidity and quality of life data will lend insight into an under-researched area of study in this disease process in the active duty military population.
